Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **fixed-dose combination** of three agents used in ophthalmology: **ketorolac** (a non-steroidal anti-inflammatory drug), **moxifloxacin** (a fourth-generation fluoroquinolone antibiotic), and **prednisolone acetate** (a synthetic corticosteroid). The combination is primarily used for the prevention and treatment of postoperative ocular inflammation and infection, especially after cataract surgery or other intraocular procedures. - **Ketorolac** inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2), reducing inflammation and pain[3]. - **Moxifloxacin** inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial replication and offering broad-spectrum antibacterial activity. - **Prednisolone acetate** binds to glucocorticoid receptors to suppress inflammation by inhibiting multiple inflammatory cytokines and mediators. This combination is intended to reduce the burden of multiple separate eye drops, improve compliance, and increase patient convenience in the perioperative period[4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketorolac + moxifloxacin + prednisolone acetate.